Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Norihito Shibata(National Institute of Health Sciences), Mikihiko Naito(Target (United States))
Cited by 51
Related Papers
Development of hybrid small molecules that induce degradation of estrogen receptor‐alpha and necrotic cell death in breast cancer cells
|Cancer Science|2013|128
Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation
|Journal of Biological Chemistry|2018|103
Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin–proteasome pathway
|Cell Death and Disease|2014|99
Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
|Chemical and Pharmaceutical Bulletin|2018|54
SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib
|Cancer Science|2017|36